Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.20.2
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Operating Costs and Expenses:        
General and administrative $ 1,286,000 $ 1,044,000 $ 2,679,000 $ 2,199,000
Research and development 1,603,000 2,594,000 3,238,000 5,012,000
Total Operating Costs and Expenses 2,889,000 3,638,000 5,917,000 7,211,000
Loss from Operations (2,889,000) (3,638,000) (5,917,000) (7,211,000)
Other Income :        
Interest income 6,000 80,000 44,000 125,000
Total Other Income 6,000 80,000 44,000 125,000
Net Loss (2,883,000) (3,558,000) (5,873,000) (7,086,000)
Net Loss Attributable to Non-controlling Interest (16,000) (27,000) (42,000) (43,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (2,867,000) (3,531,000) (5,831,000) (7,043,000)
Net Loss Attributable to Common Stockholders $ (3,322,000) $ (3,709,000) $ (6,752,000) $ (7,680,000)
Net Loss Per Share - Basic and Dilutive $ (0.18) $ (0.23) $ (0.38) $ (0.48)
Weighted average number of shares outstanding during the period - Basic and Dilutive 18,405,884 16,465,314 17,748,688 16,063,283
Series A Preferred Stock [Member]        
Other Income :        
Preferred Stock Dividends, Income Statement Impact $ (63,000) $ (61,000) $ (125,000) $ (122,000)
Series B Preferred Stock [Member]        
Other Income :        
Net Loss Attributable to Non-controlling Interest 0 0    
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0 0    
Preferred Stock Dividends, Income Statement Impact $ (392,000) $ (117,000) $ (796,000) $ (515,000)